NCCR Unveils Six New Public Service TV Announcements

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

WASHINGTON--The National Coalition for Cancer Research (NCCR), a Washington coalition of more than 20 cancer-related organizations founded in 1986, unveiled its new series of six 30-second television public service announcements at a

WASHINGTON--The National Coalition for Cancer Research (NCCR),a Washington coalition of more than 20 cancer-related organizationsfounded in 1986, unveiled its new series of six 30-second televisionpublic service announcements at a Capitol Hill ceremony. The campaignalso includes airport dioramas that repeat the TV messages.

Speaking about the budget process in which the 104th Congressis currently engaged, Rep. John Porter (R-Ill) reassured the Coalition:"Everybody agrees that downsizing is necessary, but cancerresearch is one place where we definitely do not want to cut."

Rep. Porter, chairman of the House Appropriations Subcommitteeon Labor, Health and Human Services, and Education and RelatedAgencies, pointed out in his talk that biomedical research isimportant not only for its role in finding ways to prevent andcure cancer, but also for the overall economy, since such researchprovides the country with "thousands of high-tech jobs."

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content